IntriCon (IIN) To Report Q3 Earnings: What's In The Cards?

IntriCon Corporation (NASDAQ:IIN) is scheduled to report third-quarter 2018 results on Nov 5.

Notably, the company has surpassed the Zacks Consensus Estimate in the trailing four quarters, recording average positive surprise of 158.34%.

In the last reported quarter, IntriCon reported non-GAAP earnings of 25 cents per share, increasing significantly from 9 cents in the year-ago quarter and 10 cents in the previous quarter. The figure also topped the Zacks Consensus Estimate by 15 cents.

Revenues increased 33.9% year over year and 18.9% sequentially to $30.2 million. The figure also surpassed of the Zacks Consensus Estimate of $26 million.

The strong performance of its medical, direct-to-end-consumer and indirect-to-end-consumer value hearing health businesses drove year-over-year growth.

For the third quarter, the company expects revenues to lie between $30 million and $31 million. The Zacks Consensus Estimate is pegged at $30.2 million.

Coming to the price performance, shares of IntriCon have returned 115% on a year-to-date basis against the industry’s decline of 14.3%.

Let’s see how things are shaping up for this quarter.

Factors to Consider

The company’s strong growth initiatives and solid momentum across its vast customer base on the back of its strong primary businesses are major positives.

Further, IntriCon’s third-quarter results are anticipated to be aided by its robust medical business. Its strengthening relationship with its largest customer, Medtronic (NYSE:MDT) remains the key growth driver of this business.

Moreover, growing production and sale of Medtronic’s MiniMed wireless continuous glucose monitoring (CGM) systems are likely to aid revenue generation within this business. Further, the system demand is expected to sustain its rising trend. Additionally, the company’s expanding molding capacity remains positive.

Further, IntriCon’s strengthening value based direct-to-end-consumer and indirect-to-end-consumer divisions are likely to aid the performance of its hearing health business in the to-be-reported quarter.

The company’s strong initiatives toward expanding its footprint in the underserved market on the back of its strong hearing healthcare components are a key catalyst. Further, its expanding hearing health technology portfolio is anticipated to drive the sales within this business.

What Our Model Says

According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chance of beating estimates if it also has a positive Earnings ESP. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

IntriCon has a Zacks Rank #2 and an Earnings ESP of 0.00%, making the surprise prediction difficult.

Stocks That Warrant a Look

Here are few stocks worth considering as our model shows that it has the right combination of elements to deliver an earnings beat in the upcoming releases.

AMETEK (NYSE:AME) has an Earnings ESP of +0.71% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Adobe Systems Incorporated (NASDAQ:ADBE) has an Earnings ESP of +0.19% and a Zacks Rank #2.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>